Impact of HSV-2 Therapy on HIV Incidence in Sub-Saharan Africa
Author Information
Author(s): White R G, Freeman E E, Orroth K K, Bakker R, Weiss H A, O’Farrell N, Buvé A, Hayes R J, Glynn J R
Primary Institution: London School of Hygiene and Tropical Medicine
Hypothesis
What is the potential population-level impact of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa?
Conclusion
HSV-2 therapy could potentially reduce the incidence of HIV, especially in concentrated epidemics, but requires high coverage and long duration of therapy.
Supporting Evidence
- HSV-2 infection increases HIV acquisition and transmission.
- Clinician-initiated episodic therapy had almost no effect on HIV incidence.
- Patient-initiated therapy was slightly more effective but still low without high symptom recognition.
- Suppressive therapy in concentrated epidemics can significantly reduce HIV incidence.
Takeaway
Treating herpes can help stop the spread of HIV, but we need to make sure many people get treated for a long time.
Methodology
The study used a mathematical model (STDSIM) to simulate the effects of episodic and suppressive HSV-2 therapy on HIV incidence in two cities with different HIV prevalence.
Potential Biases
Assumptions about symptom recognition and treatment-seeking behavior may not reflect actual conditions.
Limitations
The study's findings are based on model simulations, which may not fully capture real-world complexities.
Participant Demographics
The study focused on populations in Cotonou, Benin (high concentration of female sex workers) and Kisumu, Kenya (generalized epidemic).
Statistical Information
Confidence Interval
95% CI 1.9 to 3.9 for men and 95% CI 1.7 to 5.6 for women regarding HSV-2 and HIV acquisition risk ratio.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website